JP6416627B2 - ペプチドおよびその使用法 - Google Patents

ペプチドおよびその使用法 Download PDF

Info

Publication number
JP6416627B2
JP6416627B2 JP2014551387A JP2014551387A JP6416627B2 JP 6416627 B2 JP6416627 B2 JP 6416627B2 JP 2014551387 A JP2014551387 A JP 2014551387A JP 2014551387 A JP2014551387 A JP 2014551387A JP 6416627 B2 JP6416627 B2 JP 6416627B2
Authority
JP
Japan
Prior art keywords
peptide
subject
peptides
amino acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504073A (ja
JP2015504073A5 (enExample
Inventor
ゾーレン モーゲルスヴァング
ゾーレン モーゲルスヴァング
コハバ ゲルバー
コハバ ゲルバー
Original Assignee
セルピン ファーマ リミテッド ライアビリティ カンパニー
セルピン ファーマ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルピン ファーマ リミテッド ライアビリティ カンパニー, セルピン ファーマ リミテッド ライアビリティ カンパニー filed Critical セルピン ファーマ リミテッド ライアビリティ カンパニー
Publication of JP2015504073A publication Critical patent/JP2015504073A/ja
Publication of JP2015504073A5 publication Critical patent/JP2015504073A5/ja
Application granted granted Critical
Publication of JP6416627B2 publication Critical patent/JP6416627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014551387A 2012-01-09 2013-01-07 ペプチドおよびその使用法 Active JP6416627B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US61/584,517 2012-01-09
US201261699571P 2012-09-11 2012-09-11
US61/699,571 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (3)

Publication Number Publication Date
JP2015504073A JP2015504073A (ja) 2015-02-05
JP2015504073A5 JP2015504073A5 (enExample) 2016-02-25
JP6416627B2 true JP6416627B2 (ja) 2018-10-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551387A Active JP6416627B2 (ja) 2012-01-09 2013-01-07 ペプチドおよびその使用法

Country Status (10)

Country Link
US (6) US9951104B2 (enExample)
EP (2) EP3381461B1 (enExample)
JP (1) JP6416627B2 (enExample)
AU (3) AU2013208293B2 (enExample)
CA (2) CA3077804C (enExample)
DK (2) DK3381461T3 (enExample)
ES (2) ES2871544T3 (enExample)
IL (1) IL233481A0 (enExample)
MX (1) MX365403B (enExample)
WO (1) WO2013106273A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106273A2 (en) 2012-01-09 2013-07-18 Serpin Pharma, Llc Peptides and methods of using same
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
US20160194365A1 (en) 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
JP6806685B2 (ja) * 2014-09-16 2021-01-06 バイオインセプト、エルエルシー 急性放射線症候群を治療するための組成物及び方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160256611A1 (en) * 2015-03-04 2016-09-08 Microvention, Inc. Drug Delivery Device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018003928A2 (pt) * 2015-08-28 2018-09-25 Serpin Pharma Llc métodos para o tratamento de doenças
CN108602787A (zh) 2015-11-09 2018-09-28 库特克希米公司 精氨酸牙龈卟啉菌蛋白酶的抑制剂
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019212031A1 (ja) * 2018-05-02 2019-11-07 国立大学法人新潟大学 ペプチド及びその使用
WO2022010939A2 (en) * 2020-07-06 2022-01-13 Serpin Pharma, Llc Peptides and methods of using the same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
DE69333397T2 (de) 1992-08-27 2004-12-09 Bioclones (Proprietary) Ltd., Sandton Retro-, inverso-, und retro-inverso synthetische peptidanaloge
US5618563A (en) 1992-09-10 1997-04-08 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
NZ507308A (en) 1998-04-24 2003-01-31 Univ Florida Materials and methods for gene therapy
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
WO2003089011A1 (en) 2002-04-19 2003-10-30 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
CA2552758A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
EP1766412B1 (en) * 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090005348A1 (en) 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
KR20100080519A (ko) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US9005615B2 (en) 2010-05-06 2015-04-14 The Feinstein Institute For Medical Research Methods for treatment of inflammatory diseases
WO2013106273A2 (en) 2012-01-09 2013-07-18 Serpin Pharma, Llc Peptides and methods of using same
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
BR112018003928A2 (pt) 2015-08-28 2018-09-25 Serpin Pharma Llc métodos para o tratamento de doenças

Also Published As

Publication number Publication date
US20210188912A1 (en) 2021-06-24
CA3077804C (en) 2023-07-25
US9951104B2 (en) 2018-04-24
ES2871544T3 (es) 2021-10-29
US8975224B2 (en) 2015-03-10
ES2676028T3 (es) 2018-07-16
DK3381461T3 (da) 2021-05-17
EP3381461B1 (en) 2021-03-10
HK1203161A1 (en) 2015-10-23
BR112014016734A2 (pt) 2020-10-27
AU2019253814B2 (en) 2022-03-10
EP3381461A1 (en) 2018-10-03
US10899797B2 (en) 2021-01-26
MX365403B (es) 2019-05-31
DK2802338T3 (en) 2018-06-14
US20140378372A1 (en) 2014-12-25
AU2019253814A1 (en) 2019-11-14
US20170029465A9 (en) 2017-02-02
AU2013208293A2 (en) 2016-01-28
WO2013106273A2 (en) 2013-07-18
MX2014007799A (es) 2014-10-24
AU2013208293A1 (en) 2014-06-26
CA3077804A1 (en) 2013-07-18
AU2013208293B2 (en) 2017-08-10
JP2015504073A (ja) 2015-02-05
US20130274187A1 (en) 2013-10-17
US10214562B2 (en) 2019-02-26
US20250346632A1 (en) 2025-11-13
US12291581B2 (en) 2025-05-06
WO2013106273A3 (en) 2013-12-19
EP2802338A2 (en) 2014-11-19
CA2859777A1 (en) 2013-07-18
CA2859777C (en) 2020-06-30
EP2802338B1 (en) 2018-03-07
AU2017258892B2 (en) 2019-11-14
IL233481A0 (en) 2014-08-31
US20150133375A1 (en) 2015-05-14
US20200017550A1 (en) 2020-01-16
AU2017258892A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
JP6416627B2 (ja) ペプチドおよびその使用法
JP6929272B2 (ja) 疾患処置のための方法
JP2018531221A6 (ja) 疾患処置のための方法
WO2014197524A2 (en) Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
HK1260357A1 (en) Peptides and methods of using same
HK1260357B (en) Peptides and methods of using same
HK1203161B (en) Peptides and methods of using same
HK40056903B (zh) 用於疾病治疗的方法
BR112014016734B1 (pt) Composições compreendendo um peptídeo e usos de composições e peptídeos no tratamento médico
HK1258994B (zh) 用於疾病治疗的方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181004

R150 Certificate of patent or registration of utility model

Ref document number: 6416627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250